



Clinical trial results:

A Phase 1/Phase 2 Study Of CP-751,871 In Subjects With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors (ESFT)

Summary

EudraCT number	2007-004486-17
Trial protocol	GB DE NL ES FR IT
Global end of trial date	24 October 2012

Results information

Result version number	v1 (current)
This version publication date	09 March 2016
First version publication date	01 August 2015

Trial information

Trial identification

Sponsor protocol code	A4021020
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00560235
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center , Pfizer Inc. , 1 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc. , 1 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 June 2013
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	24 October 2012
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to define the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of CP-751,871 in adolescents (10-18 years) and to define the efficacy of CP-751,871 in terms of objective response rate, in subjects 10 years and older with relapsed or refractory ESFT.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 March 2008
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	2 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	France: 23
Country: Number of subjects enrolled	Germany: 23
Country: Number of subjects enrolled	Italy: 22
Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	United States: 29
Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	Chile: 8
Country: Number of subjects enrolled	Brazil: 4
Country: Number of subjects enrolled	Israel: 3
Worldwide total number of subjects	138
EEA total number of subjects	86

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	13
Adolescents (12-17 years)	65
Adults (18-64 years)	60
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were recruited separately for Phase 1 and Phase 2. A total of 138 subjects were assigned to received study treatment (31 subjects for Phase 1 and 107 subjects for Phase 2).

Pre-assignment

Screening details:

Subjects were enrolled in 66 centres of Spain, France, United Kingdom, Germany and Italy. Study started from 18 Mar 2008 and completed on 24 Oct 2012.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Figitumumab Dose Escalation (Phase 1)

Arm description:

Figitumumab intravenous (IV) administration every 4 weeks (1 cycle). Oral rapamycin could have been added as salvage therapy.

Arm type	Experimental
Investigational medicinal product name	Rapamycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

Investigational medicinal product name	Figitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Figitumumab 20 milligram per kilogram (mg/kg) IV administered every 4 weeks (1 cycle). If no dose-limiting toxicity (DLT) was identified in the 20-mg/kg cohort, dose escalation proceeded to 30-mg/kg.

Arm title	Figitumumab Dose Extension (Phase 1B)
------------------	---------------------------------------

Arm description:

Figitumumab IV administration every 4 weeks (1 cycle). Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

Arm type	Experimental
Investigational medicinal product name	Rapamycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

Investigational medicinal product name	Figitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use
Dosage and administration details:	
Figitumumab 20 mg/kg or 30 mg/kg IV administered every 4 weeks (1 cycle).	
Arm title	Figitumumab 30 mg/kg (Phase 2)

Arm description:

Figitumumab administration every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal. Oral rapamycin could have been added as salvage therapy.

Arm type	Experimental
Investigational medicinal product name	Rapamycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

Investigational medicinal product name	Figitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Figitumumab 30 mg/kg IV administered every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal.

Number of subjects in period 1	Figitumumab Dose Escalation (Phase 1)	Figitumumab Dose Extension (Phase 1B)	Figitumumab 30 mg/kg (Phase 2)
Started	10	21	107
Completed	2	2	10
Not completed	8	19	97
'Discontinued '	8	19	96
'Ongoing at Date of Cut-Off '	-	-	1

Baseline characteristics

Reporting groups

Reporting group title	Figitumumab Dose Escalation (Phase 1)
Reporting group description: Figitumumab intravenous (IV) administration every 4 weeks (1 cycle). Oral rapamycin could have been added as salvage therapy.	
Reporting group title	Figitumumab Dose Extension (Phase 1B)
Reporting group description: Figitumumab IV administration every 4 weeks (1 cycle). Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.	
Reporting group title	Figitumumab 30 mg/kg (Phase 2)
Reporting group description: Figitumumab administration every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal. Oral rapamycin could have been added as salvage therapy.	

Reporting group values	Figitumumab Dose Escalation (Phase 1)	Figitumumab Dose Extension (Phase 1B)	Figitumumab 30 mg/kg (Phase 2)
Number of subjects	10	21	107
Age categorical Units: Subjects			
10 to <13 years	2	3	17
13 to <18 years	3	13	30
18 to <30 years	5	5	43
30 to <41 years	0	0	10
≥41 years	0	0	7
Gender categorical Units: Subjects			
Female	4	7	40
Male	6	14	67

Reporting group values	Total		
Number of subjects	138		
Age categorical Units: Subjects			
10 to <13 years	22		
13 to <18 years	46		
18 to <30 years	53		
30 to <41 years	10		
≥41 years	7		
Gender categorical Units: Subjects			
Female	51		
Male	87		

End points

End points reporting groups

Reporting group title	Figitumumab Dose Escalation (Phase 1)
Reporting group description: Figitumumab intravenous (IV) administration every 4 weeks (1 cycle). Oral rapamycin could have been added as salvage therapy.	
Reporting group title	Figitumumab Dose Extension (Phase 1B)
Reporting group description: Figitumumab IV administration every 4 weeks (1 cycle). Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.	
Reporting group title	Figitumumab 30 mg/kg (Phase 2)
Reporting group description: Figitumumab administration every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal. Oral rapamycin could have been added as salvage therapy.	
Subject analysis set title	Figitumumab 20 mg/kg Dose Escalation (Phase 1)
Subject analysis set type	Sub-group analysis
Subject analysis set description: Figitumumab 20 mg/kg IV was administered every 4 weeks (1 cycle).	
Subject analysis set title	Figitumumab 30 mg/kg Dose Escalation (Phase 1)
Subject analysis set type	Sub-group analysis
Subject analysis set description: Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).	
Subject analysis set title	Figitumumab 30 mg/kg Dose Extension (Phase 1B)
Subject analysis set type	Sub-group analysis
Subject analysis set description: Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).	

Primary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR) ^{[1][2]}
End point description: Percentage of subjects with objective response based on assessment of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target and non-target disease and no new lesions. PR was defined as greater than or equal to (\geq) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. This analysis included all enrolled subjects with Ewing's sarcoma family of tumors (ESFT) and who started treatment with figitumumab.	
End point type	Primary
End point timeframe: Baseline and every cycle (4 weeks) for up to 6 cycles	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported for this end point. [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This end point was planned to be assessed for subjects in "Figitumumab 30 mg/kg (Phase 2)" reporting arm only.	

End point values	Figitumumab 30 mg/kg (Phase 2)			
Subject group type	Reporting group			
Number of subjects analysed	106 ^[3]			
Units: percentage of subjects				
number (confidence interval 95%)	14.2 (8.1 to 22.3)			

Notes:

[3] - Number of evaluable subjects for this end point.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (PFS)

End point title	Progression-Free Survival (PFS) ^[4]
-----------------	--

End point description:

PFS was the time in months from start date to date of first documentation of progression, death due to any cause or symptomatic deterioration (global deterioration of health status requiring discontinuation of treatment). This analysis included all enrolled subjects with ESFT and who started treatment with figitumumab.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and every cycle (4 weeks), until progression or death

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point was planned to be assessed for subjects in "Figitumumab 30 mg/kg (Phase 2)" reporting arm only.

End point values	Figitumumab 30 mg/kg (Phase 2)			
Subject group type	Reporting group			
Number of subjects analysed	107			
Units: months				
median (confidence interval 95%)	1.9 (1.8 to 2.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS) ^[5]
-----------------	--------------------------------------

End point description:

Time in months from enrollment to death. For subjects who were alive, overall survival was censored at the last contact. This analysis included all enrolled subjects with ESFT and who started treatment with figitumumab.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and every 2 cycles (8 weeks), until death or up to 6 cycles after date of enrollment

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point was planned to be assessed for subjects in

"Figitumumab 30 mg/kg (Phase 2)" reporting arm only.

End point values	Figitumumab 30 mg/kg (Phase 2)			
Subject group type	Reporting group			
Number of subjects analysed	107			
Units: months				
median (confidence interval 95%)	8.9 (7.2 to 10.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (Cmax)

End point title	Maximum Observed Plasma Concentration (Cmax)
End point description: The pharmacokinetic (PK) analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results; n=number of subjects evaluable for this measure at specified time points for each arm group, respectively.	
End point type	Secondary
End point timeframe: Cycle 1 and Cycle 5: 1 hour post-infusion on Day 1	

End point values	Figitumumab 20 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Extension (Phase 1B)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	6	21	
Units: milligrams per liter (mg/L)				
geometric mean (geometric coefficient of variation)				
Cycle 1 (n=4, 6, 21)	513.2 (± 42)	1075 (± 21)	975.6 (± 26)	
Cycle 5 (n=2, 2, 8)	729 (± 47)	1133 (± 9)	1043 (± 47)	

Statistical analyses

No statistical analyses for this end point

Secondary: Minimum Observed Plasma Trough Concentration (Cmin)

End point title	Minimum Observed Plasma Trough Concentration (Cmin)
-----------------	---

End point description:

C_{min} is the concentration at the end of treatment cycle (next cycle predose). The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results.

Here "99999" in the geometric coefficient of variation (CV) signifies not available (NA). Geometric CV was not calculated as only 1 subject was evaluated for this time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 6: predose on Day 1

End point values	Figitumumab 20 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Extension (Phase 1B)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	1 ^[6]	1 ^[7]	7 ^[8]	
Units: mg/L				
geometric mean (geometric coefficient of variation)	389 (± 99999)	345 (± 99999)	283.6 (± 53)	

Notes:

[6] - Number of subjects evaluated for measure.

[7] - Number of subjects evaluated for measure.

[8] - Number of subjects evaluated for measure.

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentration at End of Infusion (Cendinf)

End point title	Plasma Concentration at End of Infusion (Cendinf)
-----------------	---

End point description:

The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results; n=number of subjects evaluable for this measure at specified time points for each arm group, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 2 and Cycle 5 Day 1

End point values	Figitumumab 20 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Extension (Phase 1B)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	6	21	
Units: mg/L				
geometric mean (geometric coefficient of variation)				
Cycle 1 (n=4, 6, 21)	513.2 (± 42)	1075 (± 21)	975.6 (± 26)	
Cycle 5 (n=2, 2, 8)	729 (± 47)	1133 (± 9)	1043 (± 47)	

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

End point title	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
End point description: The dosing interval was 1 cycle (4 weeks) in this study. The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results. Here "99999" in the geometric coefficient of variation (CV) signifies not available (NA). Geometric CV was not calculated as only 1 subject was evaluated for this time point.	
End point type	Secondary
End point timeframe: Cycle 5: 1 hour post-infusion on Day 1	

End point values	Figitumumab 20 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Extension (Phase 1B)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	1 ^[9]	1 ^[10]	6 ^[11]	
Units: milligram*hour per liter (mg*hr/L)				
geometric mean (geometric coefficient of variation)	423000 (± 99999)	475000 (± 99999)	302900 (± 46)	

Notes:

[9] - Number of subjects evaluated for measure.

[10] - Number of subjects evaluated for measure.

[11] - Number of subjects evaluated for measure.

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

End point title	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
End point description: AUClast is the area under the plasma concentration time-curve from zero to the last measured concentration. The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results; n=number of subjects evaluable for this measure at specified time points for each arm group, respectively. Here "99999" in the geometric coefficient of variation (CV) signifies not available (NA). Geometric CV was not calculated as only 1 subject was evaluated for this time point.	

End point type	Secondary
End point timeframe:	
Cycle 1 and Cycle 5: 1 hour post-infusion on Day 1	

End point values	Figitumumab 20 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg Dose Extension (Phase 1B)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	6	21	
Units: mg*hr/L				
geometric mean (geometric coefficient of variation)				
Cycle 1 (n=3, 5, 16)	187200 (± 37)	338800 (± 16)	343000 (± 25)	
Cycle 5 (n=1, 1, 6)	423000 (± 99999)	509000 (± 99999)	310800 (± 46)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Positive Anti-Drug Antibody (ADA) Titer

End point title	Number of Subjects With Positive Anti-Drug Antibody (ADA) Titer ^[12]
-----------------	---

End point description:

Number of subjects with positive sample(s) in the ADA assay and in the neutralizing anti-drug antibodies (NAb) assay. An endpoint titer less than (<) 6.64 corresponded to negative ADA category value. This analysis included all enrolled subjects with ESFT and who started treatment with figitumumab. None of the serum samples were positive for ADAs following repeated administration of figitumumab, as indicated by an endpoint titer of <6.64.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 4 (predose on Day 1), 28 days after last dose (End-of-Treatment), and follow-up (approximately 150 days after last dose)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This end point was planned to be assessed for subjects in "Figitumumab 30 mg/kg (Phase 2)" reporting arm only.

End point values	Figitumumab 30 mg/kg (Phase 2)			
Subject group type	Reporting group			
Number of subjects analysed	107			
Units: subjects				
number (not applicable)	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 150 days after last dose of study drug

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

Reporting groups

Reporting group title	Figitumumab 30mg/kg (Phase 2)
-----------------------	-------------------------------

Reporting group description:

Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle) until unacceptable toxicity or participant withdrawal, for up to 6 cycles.

Reporting group title	Figitumumab 30 mg/kg + Rapamycin (Phase 2)
-----------------------	--

Reporting group description:

Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

Reporting group title	Figitumumab 30 mg/kg Dose Escalation (Phase 1)
-----------------------	--

Reporting group description:

Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).

Reporting group title	Figitumumab 30 mg/kg Dose Extension (Phase 1B)
-----------------------	--

Reporting group description:

Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).

Reporting group title	Figitumumab 20 mg/kg Dose Escalation (Phase 1)
-----------------------	--

Reporting group description:

Figitumumab 20 mg/kg IV was administered every 4 weeks (1 cycle).

Reporting group title	Figitumumab 30 mg/kg + Rapamycin Dose Extension (Phase 1B)
-----------------------	--

Reporting group description:

Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

Reporting group title	Figitumumab 30 mg/kg + Rapamycin Dose Escalation (Phase 1)
-----------------------	--

Reporting group description:

Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

Reporting group title	Figitumumab 20 mg/kg + Rapamycin Dose Escalation (Phase 1)
-----------------------	--

Reporting group description:

Figitumumab 20 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

Serious adverse events	Figitumumab 30mg/kg (Phase 2)	Figitumumab 30 mg/kg + Rapamycin (Phase 2)	Figitumumab 30 mg/kg Dose Escalation (Phase 1)
Total subjects affected by serious adverse events			
subjects affected / exposed	47 / 107 (43.93%)	16 / 29 (55.17%)	3 / 6 (50.00%)
number of deaths (all causes)	33	11	2
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic neoplasm			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 2	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			

subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device complication			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	22 / 107 (20.56%)	12 / 29 (41.38%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 36	0 / 15	0 / 2
deaths causally related to treatment / all	0 / 24	0 / 10	0 / 1
Pyrexia			

subjects affected / exposed	4 / 107 (3.74%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Apnoea			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Respiratory failure			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cough			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Haemoglobin decreased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Wound dehiscence			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system haemorrhage			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial hypotension			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	2 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Thrombocytopenia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal obstruction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			

Infection			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acinetobacter infection			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Figitumumab 30 mg/kg Dose Extension (Phase 1B)	Figitumumab 20 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg + Rapamycin Dose Extension (Phase 1B)
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 21 (47.62%)	2 / 4 (50.00%)	7 / 9 (77.78%)
number of deaths (all causes)	9	2	5

number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metastatic neoplasm			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			

subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device complication			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	1 / 21 (4.76%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	6 / 21 (28.57%)	2 / 4 (50.00%)	3 / 9 (33.33%)
occurrences causally related to treatment / all	0 / 6	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 7	0 / 0	0 / 2
Pyrexia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			

Pelvic pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	2 / 9 (22.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2

Cough			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	2 / 9 (22.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Haemoglobin decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Wound dehiscence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial hypotension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			

Infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acinetobacter infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Figitumumab 30 mg/kg + Rapamycin Dose Escalation (Phase 1)	Figitumumab 20 mg/kg + Rapamycin Dose Escalation (Phase 1)	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)	0 / 1 (0.00%)	
number of deaths (all causes)	3	0	

number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic neoplasm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior vena cava syndrome			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device complication			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	2 / 4 (50.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			

Pelvic pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pulmonary haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Apnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wheezing			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Haemoglobin decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Wound dehiscence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Convulsion			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central nervous system haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			

Infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acinetobacter infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis bacterial			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia streptococcal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Figitumumab 30mg/kg (Phase 2)	Figitumumab 30 mg/kg + Rapamycin (Phase 2)	Figitumumab 30 mg/kg Dose Escalation (Phase 1)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	99 / 107 (92.52%)	29 / 29 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	7 / 107 (6.54%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	8	0	0
Tumour haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Pallor			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Orthostatic hypotension			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Flushing			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Hypertension			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Vasodilatation			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Surgical and medical procedures			
Amputation			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

General disorders and administration site conditions			
Injection site extravasation			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Impaired healing			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
General physical health deterioration			
subjects affected / exposed	4 / 107 (3.74%)	5 / 29 (17.24%)	0 / 6 (0.00%)
occurrences (all)	4	8	0
Condition aggravated			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Chest pain			
subjects affected / exposed	15 / 107 (14.02%)	4 / 29 (13.79%)	0 / 6 (0.00%)
occurrences (all)	24	5	0
Asthenia			
subjects affected / exposed	13 / 107 (12.15%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	17	0	0
Catheter site pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	27 / 107 (25.23%)	10 / 29 (34.48%)	0 / 6 (0.00%)
occurrences (all)	36	12	0
Pyrexia			
subjects affected / exposed	13 / 107 (12.15%)	7 / 29 (24.14%)	0 / 6 (0.00%)
occurrences (all)	14	8	0
Pain			
subjects affected / exposed	5 / 107 (4.67%)	4 / 29 (13.79%)	0 / 6 (0.00%)
occurrences (all)	6	4	0
Peripheral swelling			

subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Oedema peripheral			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Malaise			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	4 / 107 (3.74%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	4	3	0
Mucosal dryness			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Medical device complication			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Mucous membrane disorder			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Swelling			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Social circumstances			
Immobile			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Erectile dysfunction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dysmenorrhoea			

subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Amenorrhoea			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	2	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Vaginal haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Testicular pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Scrotal swelling			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Pelvic pain			
subjects affected / exposed	4 / 107 (3.74%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Ovarian cyst			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Perineal erythema			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Alveolitis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	17 / 107 (15.89%)	9 / 29 (31.03%)	1 / 6 (16.67%)
occurrences (all)	24	15	1
Pleuritic pain			

subjects affected / exposed	3 / 107 (2.80%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	4	1	0
Pleural effusion			
subjects affected / exposed	3 / 107 (2.80%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
Oropharyngeal pain			
subjects affected / exposed	5 / 107 (4.67%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	6	3	0
Hypopnoea			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Pneumothorax			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	8 / 107 (7.48%)	4 / 29 (13.79%)	0 / 6 (0.00%)
occurrences (all)	10	5	0
Dyspnoea exertional			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	16 / 107 (14.95%)	8 / 29 (27.59%)	0 / 6 (0.00%)
occurrences (all)	18	11	0
Dysphonia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Haemoptysis			
subjects affected / exposed	3 / 107 (2.80%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	4	2	0
Wheezing			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Pulmonary pain			

subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Tachypnoea			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Respiratory tract congestion			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Rales			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Throat irritation			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Hypoxia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Painful respiration			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumomediastinum			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Sleep disorder			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Insomnia			
subjects affected / exposed	2 / 107 (1.87%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	2	2	0
Fear			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Depression			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Agitation			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Anxiety			
subjects affected / exposed	6 / 107 (5.61%)	4 / 29 (13.79%)	0 / 6 (0.00%)
occurrences (all)	7	4	0
Mood altered			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
Breath sounds abnormal			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Brain natriuretic peptide increased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Blood uric acid increased			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	5	0	0
Blood urea increased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			
subjects affected / exposed	4 / 107 (3.74%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	5	1	0
Blood alkaline phosphatase increased			
subjects affected / exposed	5 / 107 (4.67%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	7	2	0
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 107 (3.74%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	4	1	0
Alanine aminotransferase increased			

subjects affected / exposed	6 / 107 (5.61%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	11	2	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
White blood cell count decreased			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	7	0	0
Weight decreased			
subjects affected / exposed	13 / 107 (12.15%)	10 / 29 (34.48%)	0 / 6 (0.00%)
occurrences (all)	20	12	0
Transaminases increased			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Right ventricular systolic pressure increased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Haemoglobin decreased			
subjects affected / exposed	3 / 107 (2.80%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	6	1	0
Haemoglobin abnormal			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	11 / 107 (10.28%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	18	4	0
Electrocardiogram ST segment depression			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
N-terminal prohormone brain natriuretic peptide increased			

subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
White blood cell count increased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Breath sounds			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood sodium decreased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Sunburn			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Post procedural complication			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Infusion related reaction			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Humerus fracture			

subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Excoriation			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	0 / 107 (0.00%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Thermal burn			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Tibia fracture			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Stress fracture			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Cerebral palsy			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	5 / 107 (4.67%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	9	0	0
Supraventricular extrasystoles			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Sinus bradycardia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Pericardial effusion			

subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Bradycardia			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Left ventricular dysfunction			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Tricuspid valve incompetence			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Ventricular extrasystoles			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Disturbance in attention			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Dizziness			
subjects affected / exposed	3 / 107 (2.80%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
Balance disorder			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Memory impairment			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Intraventricular haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Hypotonia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Hemiparesis			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Headache			
subjects affected / exposed	19 / 107 (17.76%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	28	2	0
Facial paresis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dyskinesia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dysgeusia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Sensory loss			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Peripheral sensorimotor neuropathy			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Parosmia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Paraplegia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Paraparesis			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0

Monoparesis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Neuropathy peripheral			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Neuralgia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Motor dysfunction			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Monoplegia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Somnolence			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Tremor			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Syncope			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Spinal cord compression			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
VIIth nerve paralysis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	14 / 107 (13.08%)	9 / 29 (31.03%)	0 / 6 (0.00%)
occurrences (all)	26	11	0
Bone marrow failure			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Bone marrow oedema			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Leukocytosis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Leukopenia			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Thrombocytopenia			
subjects affected / exposed	13 / 107 (12.15%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	17	4	0
Pancytopenia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Neutropenia			
subjects affected / exposed	5 / 107 (4.67%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	6	0	0
Lymphopenia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	3 / 107 (2.80%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
Tinnitus			
subjects affected / exposed	5 / 107 (4.67%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	5	0	0
Hypoacusis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Vertigo positional subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	1 / 29 (3.45%) 1	0 / 6 (0.00%) 0
Ear discomfort subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	1 / 29 (3.45%) 1	0 / 6 (0.00%) 0
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	2 / 107 (1.87%) 2	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Eye pain subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Eye pruritus subjects affected / exposed occurrences (all)	2 / 107 (1.87%) 4	0 / 29 (0.00%) 0	1 / 6 (16.67%) 1
Lacrimation increased subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	15 / 107 (14.02%) 17	0 / 29 (0.00%) 0	1 / 6 (16.67%) 1
Pupils unequal			

subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Scleral hyperaemia			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Visual impairment			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	3	3	0
Eye movement disorder			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Abdominal distension			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Dry mouth			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	15 / 107 (14.02%)	2 / 29 (6.90%)	2 / 6 (33.33%)
occurrences (all)	19	4	3
Abdominal discomfort			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	20 / 107 (18.69%)	9 / 29 (31.03%)	0 / 6 (0.00%)
occurrences (all)	22	11	0
Aphthous stomatitis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	5 / 107 (4.67%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	5	3	0

Abdominal pain			
subjects affected / exposed	8 / 107 (7.48%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	8	3	0
Dental caries			
subjects affected / exposed	1 / 107 (0.93%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Dysphagia			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Faecal incontinence			
subjects affected / exposed	2 / 107 (1.87%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	2	2	0
Gastritis			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 107 (0.00%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Gingival bleeding			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gingival pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gingival recession			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Haematemesis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Haematochezia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

Stomatitis			
subjects affected / exposed	3 / 107 (2.80%)	6 / 29 (20.69%)	1 / 6 (16.67%)
occurrences (all)	3	7	1
Rectal haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Oesophageal pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Odynophagia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	16 / 107 (14.95%)	9 / 29 (31.03%)	2 / 6 (33.33%)
occurrences (all)	18	10	4
Mouth ulceration			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Mouth haemorrhage			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia oral			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Toothache			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Tooth discolouration			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	17 / 107 (15.89%)	9 / 29 (31.03%)	0 / 6 (0.00%)
occurrences (all)	17	12	0

Cheilitis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Retching			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Alopecia			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Acne			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Psoriasis			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Pruritus			
subjects affected / exposed	7 / 107 (6.54%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	7	1	0
Photosensitivity reaction			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Nail disorder			

subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	5 / 107 (4.67%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	5	1	0
Hirsutism			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hair growth abnormal			
subjects affected / exposed	3 / 107 (2.80%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
Erythema			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Ingrowing nail			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	6 / 107 (5.61%)	4 / 29 (13.79%)	0 / 6 (0.00%)
occurrences (all)	7	5	0
Skin lesion			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Exfoliative rash			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Scar pain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin irritation			

subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Subcutaneous emphysema			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Decubitus ulcer			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Renal colic			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Proteinuria			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Polyuria			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Bladder spasm			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Micturition disorder			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Leukocyturia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Haematuria			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dysuria			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0

Pollakiuria			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Renal failure acute			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Urinary retention			
subjects affected / exposed	0 / 107 (0.00%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Urinary incontinence			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Urinary hesitation			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Renal failure chronic			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Vesicoureteric reflux			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Renal impairment			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Cushingoid			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	11 / 107 (10.28%)	5 / 29 (17.24%)	0 / 6 (0.00%)
occurrences (all)	14	7	0
Muscle spasms			

subjects affected / exposed	20 / 107 (18.69%)	5 / 29 (17.24%)	0 / 6 (0.00%)
occurrences (all)	27	6	0
Muscular weakness			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal pain			
subjects affected / exposed	11 / 107 (10.28%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	12	5	0
Muscle disorder			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Back pain			
subjects affected / exposed	17 / 107 (15.89%)	8 / 29 (27.59%)	0 / 6 (0.00%)
occurrences (all)	17	16	0
Bone pain			
subjects affected / exposed	4 / 107 (3.74%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	4	3	0
Bone swelling			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Musculoskeletal chest pain			
subjects affected / exposed	7 / 107 (6.54%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	7	4	0
Myalgia			
subjects affected / exposed	8 / 107 (7.48%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	8	3	0
Neck pain			
subjects affected / exposed	4 / 107 (3.74%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	4	2	0
Pain in extremity			
subjects affected / exposed	9 / 107 (8.41%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	9	3	0
Spinal disorder			

subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Groin pain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mobility decreased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Candida infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Device related infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	4 / 107 (3.74%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Gingivitis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis			
subjects affected / exposed	2 / 107 (1.87%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	2	2	0
Bronchopneumonia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Oral fungal infection			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0

Nasopharyngitis			
subjects affected / exposed	5 / 107 (4.67%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	6	2	0
Lung infection			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	4	0
Lower respiratory tract infection			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
H1N1 influenza			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Laryngitis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Infection			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Herpes zoster			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Localised infection			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Skin infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Otitis media acute			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Otitis media			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

Oral herpes			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	6 / 107 (5.61%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	6	1	0
Papilloma viral infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Post procedural infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Paronychia			
subjects affected / exposed	4 / 107 (3.74%)	3 / 29 (10.34%)	0 / 6 (0.00%)
occurrences (all)	7	6	0
Rhinitis			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Upper respiratory tract infection			
subjects affected / exposed	5 / 107 (4.67%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	5	0	0
Viral infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	4 / 107 (3.74%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	4	1	0
Wound infection			
subjects affected / exposed	0 / 107 (0.00%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Pneumonia primary atypical subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	0 / 29 (0.00%) 0	1 / 6 (16.67%) 1
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	12 / 107 (11.21%) 17	1 / 29 (3.45%) 2	0 / 6 (0.00%) 0
Hypermagnesaemia subjects affected / exposed occurrences (all)	2 / 107 (1.87%) 3	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Hyperphosphataemia subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	22 / 107 (20.56%) 24	13 / 29 (44.83%) 17	0 / 6 (0.00%) 0
Acidosis subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 29 (3.45%) 2	0 / 6 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	2 / 29 (6.90%) 2	0 / 6 (0.00%) 0
Hyperalbuminaemia subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Hypercalcaemia subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	1 / 29 (3.45%) 1	0 / 6 (0.00%) 0
Hypercholesterolaemia subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 29 (0.00%) 0	0 / 6 (0.00%) 0
Cachexia			

subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Hyperuricaemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypoalbuminaemia			
subjects affected / exposed	4 / 107 (3.74%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	5	1	0
Hypocalcaemia			
subjects affected / exposed	2 / 107 (1.87%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Hypophagia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	2 / 107 (1.87%)	2 / 29 (6.90%)	0 / 6 (0.00%)
occurrences (all)	2	4	0
Hyponatraemia			
subjects affected / exposed	3 / 107 (2.80%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Hypophosphataemia			
subjects affected / exposed	3 / 107 (2.80%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	5	1	0
Polydipsia			
subjects affected / exposed	2 / 107 (1.87%)	0 / 29 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Tetany			
subjects affected / exposed	0 / 107 (0.00%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Type 1 diabetes mellitus			
subjects affected / exposed	1 / 107 (0.93%)	1 / 29 (3.45%)	0 / 6 (0.00%)
occurrences (all)	1	1	0

Non-serious adverse events	Figitumumab 30 mg/kg Dose Extension (Phase 1B)	Figitumumab 20 mg/kg Dose Escalation (Phase 1)	Figitumumab 30 mg/kg + Rapamycin Dose Extension (Phase 1B)
Total subjects affected by non-serious			

adverse events			
subjects affected / exposed	19 / 21 (90.48%)	3 / 4 (75.00%)	9 / 9 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Pallor			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vasodilatation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Surgical and medical procedures			
Amputation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

Injection site extravasation subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Impaired healing subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
General physical health deterioration subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Condition aggravated subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Chest pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Asthenia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Catheter site pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0

Oedema peripheral subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Malaise subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Mucosal inflammation subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Mucosal dryness subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Medical device complication subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Mucous membrane disorder subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Swelling subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Social circumstances Immobile subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Reproductive system and breast disorders Menstruation irregular subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Amenorrhoea			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Testicular pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Scrotal swelling			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ovarian cyst			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Perineal erythema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Alveolitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	2 / 21 (9.52%)	0 / 4 (0.00%)	2 / 9 (22.22%)
occurrences (all)	2	0	2
Pleuritic pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	2 / 21 (9.52%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Hypopnoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	3 / 9 (33.33%)
occurrences (all)	1	0	3
Dyspnoea exertional			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	4 / 21 (19.05%)	0 / 4 (0.00%)	4 / 9 (44.44%)
occurrences (all)	4	0	8
Dysphonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Wheezing			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pulmonary pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	3
Rhinorrhoea			
subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Respiratory tract congestion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rales			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Throat irritation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Painful respiration			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pneumomediastinum			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Psychiatric disorders			
Sleep disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Fear			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Agitation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Investigations			
Breath sounds abnormal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Right ventricular systolic pressure increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haemoglobin abnormal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram ST segment depression			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			

subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Weight increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hepatic enzyme increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
C-reactive protein increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Breath sounds			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Blood sodium decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Sunburn			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Humerus fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Excoriation			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tibia fracture			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Stress fracture			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Congenital, familial and genetic disorders			
Cerebral palsy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Supraventricular extrasystoles			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pericardial effusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bradycardia			

subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Left ventricular dysfunction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Intraventricular haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypotonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Hypoaesthesia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hemiparesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Facial paresis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyskinesia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Peripheral sensorimotor neuropathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Parosmia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Paraplegia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Paraparesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Monoparesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Motor dysfunction subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Monoplegia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Somnolence subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 4 (0.00%) 0	1 / 9 (11.11%) 1
Tremor subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Spinal cord compression subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
VIIth nerve paralysis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	1 / 9 (11.11%) 1
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 3	0 / 4 (0.00%) 0	1 / 9 (11.11%) 1
Bone marrow failure			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bone marrow oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	2 / 21 (9.52%)	2 / 4 (50.00%)	1 / 9 (11.11%)
occurrences (all)	3	2	1
Pancytopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vertigo positional			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Ear pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ear discomfort			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Vision blurred			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Conjunctival hyperaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Eye pruritus			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	5 / 21 (23.81%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	5	0	0
Pupils unequal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Scleral hyperaemia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye movement disorder			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Abdominal distension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	5 / 21 (23.81%)	1 / 4 (25.00%)	2 / 9 (22.22%)
occurrences (all)	7	1	4
Abdominal discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	3 / 9 (33.33%)
occurrences (all)	2	0	3
Aphthous stomatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	2
Abdominal pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	1 / 9 (11.11%)
occurrences (all)	0	2	1

Dental caries			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Faecal incontinence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingival recession			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematemesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	3 / 21 (14.29%)	0 / 4 (0.00%)	2 / 9 (22.22%)
occurrences (all)	3	0	2

Rectal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oesophageal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	6 / 21 (28.57%)	1 / 4 (25.00%)	2 / 9 (22.22%)
occurrences (all)	7	1	2
Mouth ulceration			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Mouth haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tooth discolouration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1

Lip dry subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 4 (0.00%) 0	1 / 9 (11.11%) 1
Retching subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Upper gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Hepatobiliary disorders Jaundice subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatitis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Alopecia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	1 / 9 (11.11%) 1
Acne subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Psoriasis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Photosensitivity reaction subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Nail disorder subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Dry skin			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hirsutism			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hair growth abnormal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ingrowing nail			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Exfoliative rash			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Petechiae			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Rash papular			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Scar pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Skin irritation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Subcutaneous emphysema			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Decubitus ulcer			
subjects affected / exposed	0 / 21 (0.00%)	1 / 4 (25.00%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Renal colic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Polyuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bladder spasm			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Micturition disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Leukocyturia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Renal failure acute subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Urinary retention subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Urinary hesitation subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Renal failure chronic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Vesicoureteric reflux subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Renal impairment subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	1 / 9 (11.11%) 1
Endocrine disorders Cushingoid subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Inappropriate antidiuretic hormone secretion subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 4 (25.00%) 1	0 / 9 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Muscular weakness			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Muscle disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bone swelling			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Spinal disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Groin pain			

subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Mobility decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	2 / 21 (9.52%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Candida infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bronchopneumonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oral fungal infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Lung infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
H1N1 influenza			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Localised infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Otitis media acute			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Sinusitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Papilloma viral infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Post procedural infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Wound infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1

Pneumonia primary atypical subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Hypermagnesaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Hyperphosphataemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Acidosis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Hyperalbuminaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Hypercholesterolaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Cachexia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 4 (0.00%) 0	0 / 9 (0.00%) 0
Hyperuricaemia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypophagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Polydipsia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tetany			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 21 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Figitumumab 30 mg/kg + Rapamycin Dose Escalation (Phase 1)	Figitumumab 20 mg/kg + Rapamycin Dose Escalation (Phase 1)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)	1 / 1 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Tumour pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Tumour haemorrhage subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Vascular disorders Pallor subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Orthostatic hypotension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Hypotension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Hot flush subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Flushing subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Hypertension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Vasodilatation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Surgical and medical procedures Amputation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
General disorders and administration site conditions Injection site extravasation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	

Impaired healing			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Condition aggravated			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Asthenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Catheter site pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Peripheral swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Mucosal dryness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Medical device complication			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Mucous membrane disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Social circumstances			
Immobile			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Erectile dysfunction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dysmenorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Amenorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vulvovaginal pruritus			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vaginal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Testicular pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Scrotal swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pelvic pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Ovarian cyst			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Perineal erythema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Alveolitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pleuritic pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypopnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pneumothorax			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dyspnoea exertional			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dysphonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Wheezing			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pulmonary pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Tachypnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Rhinorrhoea			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Respiratory tract congestion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Rales			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Throat irritation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Painful respiration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pneumomediastinum			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Sleep disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Insomnia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Fear			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Depression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Agitation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Anxiety			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Mood altered			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Investigations			
Breath sounds abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood uric acid increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood urea increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood creatinine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
White blood cell count decreased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Transaminases increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Right ventricular systolic pressure increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Ejection fraction decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Haemoglobin decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Haemoglobin abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Electrocardiogram ST segment depression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
White blood cell count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Weight increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Neutrophil count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hepatic enzyme increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
C-reactive protein increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Breath sounds			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood sodium decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Injury, poisoning and procedural complications			
Sunburn			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Post procedural complication			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Infusion related reaction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Humerus fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Excoriation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Contusion			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Fall			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Thermal burn			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Tibia fracture			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Stress fracture			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Congenital, familial and genetic disorders			
Cerebral palsy			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Cardiac disorders			
Tachycardia			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Supraventricular extrasystoles			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Sinus bradycardia			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Pericardial effusion			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Bradycardia			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Left ventricular dysfunction			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Tricuspid valve incompetence subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Nervous system disorders			
Convulsion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Dizziness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Balance disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Memory impairment subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Lethargy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Intraventricular haemorrhage subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Hypotonia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	

Hemiparesis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Facial paresis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dyskinesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dysgeusia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Sensory loss			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Peripheral sensorimotor neuropathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Parosmia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Paraplegia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Paraparesis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Monoparesis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Neuropathy peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Neuralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Motor dysfunction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Monoplegia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Somnolence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Tremor			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Syncope			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Spinal cord compression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
VIIth nerve paralysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 1 (100.00%)	
occurrences (all)	5	3	
Bone marrow failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Bone marrow oedema			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Leukocytosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Leukopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Thrombocytopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pancytopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Lymphopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	1	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Tinnitus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypoacusis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vertigo positional			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Ear pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Ear discomfort subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Dry eye subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Eye pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Eye pruritus subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Lacrimation increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Pupils unequal subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Scleral hyperaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Visual impairment			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Eye movement disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Abdominal distension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dry mouth			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Abdominal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Constipation			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	
Aphthous stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dental caries			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Dysphagia		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Faecal incontinence		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Gastritis		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Gingival bleeding		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Gingival pain		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Gingival recession		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Haematemesis		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Haemorrhoids		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Haematochezia		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Stomatitis		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Rectal haemorrhage		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0

Oral pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oesophageal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Odynophagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Mouth ulceration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Mouth haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypoaesthesia oral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Toothache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Tooth discolouration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Cheilitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Lip dry			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Retching			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Alopecia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Acne			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Psoriasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Photosensitivity reaction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Nail disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hirsutism			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Hair growth abnormal		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Erythema		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Ingrowing nail		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Rash		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Skin lesion		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Exfoliative rash		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Petechiae		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Rash papular		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Scar pain		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Skin irritation		
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)
occurrences (all)	1	0
Subcutaneous emphysema		
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0
Decubitus ulcer		

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Renal colic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Proteinuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Polyuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Bladder spasm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Micturition disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Leukocyturia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pollakiuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Renal failure acute			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Urinary retention			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Urinary incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Urinary hesitation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Renal failure chronic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Vesicoureteric reflux			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Renal impairment			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Endocrine disorders			
Cushingoid			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Muscle spasms			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal pain			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Muscle disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Bone swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Joint swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Neck pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Spinal disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Groin pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Mobility decreased			

subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 1 (0.00%) 0	
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Candida infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Device related infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Bronchitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Gingivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Gastroenteritis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Bronchopneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oral fungal infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Oral candidiasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Lung infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
H1N1 influenza subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Laryngitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Influenza subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Herpes zoster subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Localised infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Skin infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Otitis media acute subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Otitis media subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Oral herpes subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	
Sinusitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 1 (0.00%) 0	

Papilloma viral infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Post procedural infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Paronychia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Viral infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Wound infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Pneumonia primary atypical			
subjects affected / exposed	1 / 4 (25.00%)	0 / 1 (0.00%)	
occurrences (all)	1	0	

Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypermagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hyperphosphataemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Decreased appetite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Acidosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hyperalbuminaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypercholesterolaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Cachexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hyperuricaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypoalbuminaemia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypophagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypokalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Hypophosphataemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Polydipsia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Tetany			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 June 2008	A secondary objective of collection of a blood samples for the enumeration of circulating tumor cells expressing the IGF-IR (surface protein and gene copy number) was added. Option of local therapy (such as radiation and/or surgery) in patients with durable objective responses and optional salvage therapy in combination with Rapamycin only to patients with progressive disease was added and collection of safety information about the combination of figitumumab with rapamycin was added. Valvular disease and endocarditis were added to the list of significant cardiac diseases which would preclude enrollment in the study. Additional information on the analysis of the tumor biopsies and the collection of the tumor specimens was included in the protocol.
10 March 2009	Enrollment of diabetic patients (with properly managed diabetic condition) into the study was added. Response Evaluation Criteria in Solid Tumors (RECIST) criteria was updated according to the current standard medical practice. Safety follow up visits scheduled once every other a month for up to 150 days after the last study drug administration, unless the patient withdraws consent or start a new anti-cancer treatment was added. Additional follow up study visits to monitor for any sustained, treatment emergent adverse events and patients discontinuing therapy without evidence of tumor progression were assessed every 8 weeks until disease progression even if new anticancer therapy was initiated, were added to the protocol.
08 December 2010	The protocol was amended to provide guidance for evaluation and reportability of potential cases of liver injury and clarification about preparation and administration of study drug was provided.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported